<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04357223</url>
  </required_header>
  <id_info>
    <org_study_id>Saga-002</org_study_id>
    <nct_id>NCT04357223</nct_id>
  </id_info>
  <brief_title>NOGO for an Overactive Bladder</brief_title>
  <acronym>NOGO-OAB</acronym>
  <official_title>A Parallel, Randomised, Double Blind, Placebo Controlled Study to Investigate the Effect of NOGO on Overactive Bladder in Men and Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SagaNatura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Politecnica de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SagaNatura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized and placebo-controlled study to evaluate the safety and
      effectiveness of NoGo, a standardized extract from Angelica archangelica, on overactive
      bladder
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of urination frequency (number of voids per 24 hours)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction in number of voids per 24 hours as assessed by a 3 day voiding diary before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduced number of daytime voids</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction in number of voids occurring during waking hours as assessed by a 3 day voiding diary before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced number of nocturnal voids (nocturia)</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction in number of voids occurring during sleeping hours as assessed by a 3 day voiding diary before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced number of nocturnal voids (nocturia) per hour sleeping time</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction in number of voids occurring during sleeping hours corrected by sleeping time as assessed by a 3 day voiding diary before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced number of voids occurring shortly after the last one</measure>
    <time_frame>6 weeks</time_frame>
    <description>Reduction in number of voids occurring shortly after the preceding void (less than 60, 90 and 120 minutes) as assessed by a 3 day voiding diary before and after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the results of the ICIQ-OAB</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of the results of the IPSS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Overactive Bladder</condition>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>extract from Angelica archangelica leaf</intervention_name>
    <description>A standardized extract from Angelica archangelica leaf. Capsule, Twice Daily</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected or diagnosed with overactive bladder (average â‰¥ of 1.5 nocturnal voids per
             night and/or less then 2 hours between voids at least half time of the day (question 2
             IPSS)

        Exclusion Criteria:

          -  High alcohol consumption (males &gt; 3 beers/day (36 g alcohol), females &gt;2 beers/day (24
             g alcohol), but we take weekly average.

        Abnormal urinary findings suggestive of urinary tract infection, significant hematuria or
        glucosuria requiring further evaluation.

        Chronic incontinence. Recurrent urinary tract infections (3 or more times per year).
        Pregnancy, lactation, last child born at least one year before, uterine prolapse,
        histerectomy Surgical treatment for bladder outlet obstruction/BPH performed within the
        past 6 months. Moderate to severe prostate hyperplasia (IPSS questionnaire).

        Medical history or active conditions which, in the opinion of the principal investigator
        (PI) and physicians participating in the study would prohibit participation in the study.
        This includes, but is not limited to: diabetes, cancer, renal failure, cirrhosis or chronic
        liver disease, pancreatic diseases, recent (&lt;6 months) myocardial infarction or unstable
        coronary artery disease.

        Psychiatric diseases and medication. Use of NoGO or other products containing A.
        archangelica extract within the previous 2 months prior to randomisation.

        Known allergy to compound or any other ingredients of NoGo. Supplements like pumpkin seeds,
        natural products with diuretic effect. Not exclusion if they have a wash out period.

        Receipt of an investigational product within 30 days prior to enrolment or expected receipt
        during this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcela Gonzalez-Gross, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>INEF- Universidad Politecnica de Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcela Gonzalez-Gross, Ph.D.</last_name>
    <phone>34 91 0677980</phone>
    <email>marcela.gonzalez.gross@upm.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universidad Politecnica de Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Marcela Gonzalez-Gross, Ph.D.</last_name>
      <phone>+34 91 0677980</phone>
      <email>marcela.gonzalez.gross@upm.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 20, 2020</study_first_submitted>
  <study_first_submitted_qc>April 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

